Avecho Biotechnology Limited (AU:AVE)
ASX:AVE
Top Page
Avecho Biotechnology Limited
(Sydney:AVE)
Select Model
Select Model
Rating:53Neutral
Price Target:
AU$0.01
▲(20.00% Upside)
Action:ReiteratedDate:03/06/26
The score is driven primarily by mixed financial performance: improving revenue and a 2025 shift to positive operating/free cash flow and low debt are positives, but persistent losses and shrinking equity remain major risks. Technicals add modest support from near-term price strength, while valuation is constrained by negative earnings and no indicated dividend.
Positive Factors
Proprietary TPM platform & licensing model
Avecho's proprietary Tocopheryl Phosphate Mixture (TPM) is a durable platform asset that supports a licensing/partnering business model. Platform-led strategies can generate recurring royalties and milestone income, leverage partner commercial scale, and lower Avecho's capex needs versus direct large-scale manufacturing.
Negative Factors
Persistent operating and net losses
Consistent, sizable operating and net losses erode intrinsic value and indicate the business still requires profitability improvement. Over the medium term this increases the need for external funding or material margin improvement from partners, constraining strategic flexibility and investor returns.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary TPM platform & licensing model
Avecho's proprietary Tocopheryl Phosphate Mixture (TPM) is a durable platform asset that supports a licensing/partnering business model. Platform-led strategies can generate recurring royalties and milestone income, leverage partner commercial scale, and lower Avecho's capex needs versus direct large-scale manufacturing.
Read all positive factors
Avecho Biotechnology Limited (AVE) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$29.39M
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)1.37
Revenue Growth306.88%
EPS GrowthN/A
CountryAU
Employees29
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding3,673,463,600
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio-0.17
Price to Book (P/B)18.85
Price to Sales (P/S)23.75
P/FCF Ratio26.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Avecho Biotechnology Limited Business Overview & Revenue Model
Company Description
Avecho Biotechnology Limited, a biotechnology company, develops, produces, and sells products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, skin care, animal health, and nutr...
How the Company Makes Money
Avecho Biotechnology Limited generates revenue primarily through the development and licensing of its proprietary TPM technology to pharmaceutical and healthcare companies. The company earns income by entering into licensing agreements with partne...
Avecho Biotechnology Limited Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
52
Neutral
Cash Flow
57
Neutral
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.24M | 1.13M | 473.55K | 1.13M | 793.60K |
| Gross Profit | 751.29K | 671.93K | -43.80K | 793.12K | 507.94K |
| EBITDA | -5.87M | -2.92M | -3.24M | -2.11M | -2.98M |
| Net Income | -4.42M | -3.12M | -3.44M | -2.34M | -3.42M |
Balance Sheet | |||||
| Total Assets | 7.11M | 5.00M | 7.32M | 3.35M | 5.25M |
| Cash, Cash Equivalents and Short-Term Investments | 4.66M | 2.37M | 5.50M | 1.47M | 3.26M |
| Total Debt | 14.47K | 1.08M | 175.15K | 246.07K | 93.91K |
| Total Liabilities | 5.55M | 1.73M | 941.54K | 920.66K | 709.36K |
| Stockholders Equity | 1.56M | 3.27M | 6.38M | 2.42M | 4.54M |
Cash Flow | |||||
| Free Cash Flow | 1.10M | -3.97M | -3.18M | -1.72M | -3.30M |
| Operating Cash Flow | 1.10M | -3.97M | -3.18M | -1.67M | -3.10M |
| Investing Cash Flow | 0.00 | -15.73K | 0.00 | -53.12K | -202.82K |
| Financing Cash Flow | 1.19M | 854.59K | 7.22M | -78.22K | 4.69M |
Avecho Biotechnology Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | AU$29.39M | -2.50 | -370.40% | ― | 306.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | AU$8.84M | -0.15 | 2844.96% | ― | ― | 46.28% | |
45 Neutral | AU$17.08M | -1.59 | -91.88% | ― | -93.83% | 20.00% | |
43 Neutral | AU$8.82M | -1.29 | -43.95% | ― | 48.63% | 25.66% | |
43 Neutral | AU$17.82M | -3.69 | 2509.60% | ― | ― | -36.89% | |
42 Neutral | AU$25.29M | -6.84 | -49.25% | ― | ― | ― |
* Healthcare Sector Average
AU:AVE
Avecho Biotechnology Limited
0.01
0.00
0.00%
AU:1AI
Living Cell Technologies
0.01
<0.01
40.00%
AU:IMC
Immuron Limited
0.03
-0.04
-59.09%
AU:NOX
Noxopharm Ltd.
0.06
-0.01
-15.94%
AU:CHM
Chimeric Therapeutics Ltd.
―
―
―
AU:MEM
Memphasys Ltd
―
―
―
Avecho Biotechnology Limited Corporate Events
Avecho hits key Phase III recruitment milestone in CBD insomnia trial
Mar 1, 2026
Avecho Biotechnology has completed recruitment of roughly 210 patients for the interim analysis cohort of its pivotal Phase III trial of a TPM-enhanced cannabidiol capsule for insomnia, with results expected in June 2026. The study is intended to ...
Avecho Files Updated Corporate Governance Statement and Appendix 4G with ASX
Feb 27, 2026
Avecho Biotechnology Limited has lodged its Corporate Governance Statement for the financial year ended 31 December 2025, confirming that the document is current as of 27 February 2026 and has been approved by the board. The statement, accessible ...
Avecho Widens Annual Loss Despite Higher Revenue as Development Spending Continues
Feb 27, 2026
Avecho Biotechnology Limited has reported a 9.3% increase in revenues from ordinary activities to $1.24 million for the year ended 31 December 2025, while its net tangible assets per ordinary security declined to 0.04 cents from 0.10 cents. The co...
Avecho nears key Phase III milestone as CEO showcases CBD insomnia program at healthcare forum
Feb 4, 2026
Avecho Biotechnology has announced that CEO Dr Paul Gavin will present at the Euroz Hartleys Healthcare Forum, where he will provide an update on the company’s pivotal Phase III clinical trial of its CBD TPM soft-gel capsule for insomnia and...
Avecho Advances Phase III CBD Insomnia Trial, Raises Capital and Secures US/EU Patent Wins
Jan 29, 2026
Avecho Biotechnology reported solid progress in its pivotal Phase III trial of its CBD TPM® soft-gel capsule for insomnia, with 190 of the roughly 210 patients required for the interim analysis already dosed and remaining recruitment continui...
Avecho Nears Completion of Recruitment for Phase III CBD Trial
Dec 18, 2025
Avecho Biotechnology has announced nearing the completion of recruitment for its pivotal Phase III clinical trial for a CBD-enhanced capsule aimed at treating insomnia, with 190 out of the targeted 210 participants already dosed. The successful ou...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.